Resverlogix raises $2.3 mln from NGN-led private placement
Resverlogix Corp (TSX: RVX) has closed a private placement of 3.5 million common shares at a price of $0.65 per share for gross proceeds of $2.3 million. U.S. healthcare-focused venture capital firm NGN Capital, which has backed the company since 2009, accounted for most of the investment, with the balance taken by Resverlogix directors and officers. The Calgary-based clinical stage cardiovascular company plans to use proceeds from the offering to fund research and development activities, general and administrative expenses, increased working capital and other general corporate purposes.
11 June 2014•3 mins read
